Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma

被引:23
|
作者
Pozzobon, F. C. [1 ,4 ,5 ]
Puig-Butille, J. A. [2 ,6 ]
Gonzalez-Alvarez, T. [1 ,4 ,7 ]
Carrera, C. [1 ,4 ,6 ]
Aguilera, P. [1 ,4 ,6 ]
Alos, L. [3 ,8 ]
Badenas, C. [2 ,6 ]
Grichnik, J. M. [9 ]
Malvehy, J. [1 ,4 ,6 ]
Puig, S. [1 ,4 ,6 ,8 ]
机构
[1] Hosp Clin Barcelona, Dept Dermatol, Barcelona, Spain
[2] Hosp Clin Barcelona, Biochem & Mol Genet Serv, Barcelona, Spain
[3] Hosp Clin Barcelona, Melanoma Unit, Pathol Serv, Barcelona, Spain
[4] IDIBAPS, Barcelona, Spain
[5] Univ Nacl Colombia, Bogota, Colombia
[6] ISCIII, CIBERER, Barcelona, Spain
[7] Univ CES, Medellin, Colombia
[8] Univ Barcelona, Dept Med, Barcelona, Spain
[9] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA
关键词
ANTITUMOR-ACTIVITY; FEATURES; IMMUNOTHERAPY; INFILTRATION;
D O I
10.1111/bjd.13069
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background The identification of BRAF mutations in melanoma led to the development and implementation of new and effective therapies. Few clinical and histological features have been associated with this mutational status. Objectives The main objective of this study was to investigate clinical, histopathological and dermoscopic characteristics of primary melanomas according to BRAF or NRAS mutational status. Methods An observational retrospective study including melanoma dermoscopy images assessed for somatic mutations in BRAF and NRAS. Results Seventy-two patients were included, 30 women (42%) and 42 men (58%), mean age was 591551years. BRAF-mutated melanomas were more frequently located on the trunk (n=18, 64% for BRAF-mutated vs. n=11, 29% for wild-type melanomas, P=0013). Histological ulceration was associated with the presence of BRAF mutations [odds ratio (OR) 3141; 95% confidence interval (CI) 1289-7655; P=0002]. The Breslow index tended to be thicker in BRAF-mutated compared with wild-type (P=0086). BRAF mutations were present in 28 (39%) patients and only four cases were positive for NRAS mutations (6%), BRAF and NRAS mutations being mutually exclusive. The presence of dermoscopic peppering was associated with MAPK mutations (BRAF and NRAS) (OR 168; 95% CI 1089-2581; P=0015). Dermoscopic ulceration was also associated with BRAF mutations excluding acral and facial melanomas (OR 264; 95% CI 1032-6754). Conclusions This study showed a correlation between BRAF and NRAS status and dermoscopic findings of peppering' as an expression of regression and melanophages in the dermis, suggesting a morphological consequence of immune behaviour in BRAF-mutated melanomas.
引用
收藏
页码:754 / 759
页数:6
相关论文
共 50 条
  • [1] Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil
    Gouillon, L.
    Perier-Muzet, M.
    Amini-Adle, M.
    Poulalhon, N.
    Debarbieux, S.
    Boespflug, A.
    Balme, B.
    Depaepe, L.
    Harou, O.
    Lopez, J.
    Bringuier, P. -P.
    Ferraro-Peyret, C.
    Maucort-Boulch, D.
    Robinson, P.
    Thomas, L.
    Dalle, S.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (02) : E57 - E59
  • [2] Clinicopathological features and NRAS gene mutation status in patients with primary cutaneous melanoma
    Aksenenko, M.
    Ruksha, T.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S247 - S247
  • [3] Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma
    Goel, Vikas K.
    Lazar, Alexander J. F.
    Warneke, Carla L.
    Redston, Mark S.
    Haluska, Frank G.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 (01) : 154 - 160
  • [4] NRAS and BRAF mutation frequency in primary oral mucosal melanoma
    Buery, Rosario Rivera
    Siar, Chong Huat
    Katase, Naoki
    Gunduz, Mehmet
    Lefeuvre, Mathieu
    Fujii, Masae
    Inoue, Masahisa
    Setsu, Kojun
    Nagatsuka, Hitoshi
    [J]. ONCOLOGY REPORTS, 2011, 26 (04) : 783 - 787
  • [5] Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies
    Saldanha, Gerald
    Potter, Linda
    DaForno, Philip
    Pringle, J. Howard
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (15) : 4499 - 4505
  • [6] BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma
    Garcia-Casado, Z.
    Traves, V.
    Banuls, J.
    Niveiro, M.
    Gimeno-Carpio, E.
    Jimenez-Sanchez, A. I.
    Moragon, M.
    Onrubia, J. A.
    Oliver, V.
    Kumar, R.
    Nagore, E.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (04) : 1128 - 1131
  • [7] BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma
    van Not, Olivier J.
    Blokx, Willeke A. M.
    van den Eertwegh, Alfons J. M.
    de Meza, Melissa M.
    Haanen, John B.
    Blank, Christian U.
    Aarts, Maureen J. B.
    van den Berkmortel, Franchette W. P. J.
    de Groot, Jan Willem B.
    Hospers, Geke A. P.
    Kapiteijn, Ellen
    Piersma, Djura
    van Rijn, Rozemarijn S.
    Stevense-den Boer, Marion
    van der Veldt, Astrid A. M.
    Boers-Sonderen, Marye J.
    Jansen, Anne M. L.
    Wouters, Michel W. J. M.
    Suijkerbuijk, Karijn P. M.
    [J]. JCO PRECISION ONCOLOGY, 2022, 6
  • [8] BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma
    van Not, Olivier J.
    Blokx, Willeke A. M.
    van den Eertwegh, Alfons J. M.
    de Meza, Melissa M.
    Haanen, John B.
    Blank, Christian U.
    Aarts, Maureen J. B.
    van den Berkmortel, Franchette W. P. J.
    de Groot, Jan Willem B.
    Hospers, Geke A. P.
    Kapiteijn, Ellen
    Piersma, Djura
    van Rijn, Rozemarijn S.
    Boer, Marion Stevense-den
    Van der Veldt, Astrid A. M.
    Boers-Sonderen, Marye J.
    Jansen, Anne M. L.
    Wouters, Michel W. J. M.
    Suijkerbuijk, Karijn P. M.
    [J]. JCO PRECISION ONCOLOGY, 2022, 6
  • [9] Dermoscopic Features as Predictors of BRAF Mutational Status and Sentinel Lymph Node Positivity in Primary Cutaneous Melanoma
    Filipovic, Nika
    Situm, Mirna
    Buljan, Marija
    [J]. DERMATOLOGY PRACTICAL & CONCEPTUAL, 2021, 11 (02):
  • [10] BRAF and NRAS mutation status and response to checkpoint inhibition in advanced melanoma.
    van Not, Olivier Jules
    van den Eertwegh, Alfonsus Johannes Maria
    Haanen, John B. A. G.
    Blank, Christian U.
    Aarts, Maureen J. B.
    van den Berkmortel, Franchette
    de Groot, Jan Willem
    Hospers, Geke
    Kapiteijn, Ellen
    Piersma, Djura
    Van Rijn, Rozemarijn
    Stevense, Marion
    Van Der Veldt, Astrid Aplonia Maria
    Vreugdenhil, Gerard
    Boers-Sonderen, Marye
    Bonenkamp, Han J.
    Jansen, Anne M. L.
    Blokx, Willeke
    Wouters, Michel W. J. M.
    Suijkerbuijk, Karijn
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)